{
    "clinical_study": {
        "@rank": "77130", 
        "arm_group": [
            {
                "arm_group_label": "Formulation A followed by Formulation B", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Formulation B followed by Formulation A", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to investigate the bioequivalence\n      (assessment of the expected biological equivalence of two pharmaceutical drug products with\n      identical active ingredient) between subcutaneous injections of semaglutide produced by two\n      manufacturing processes."
        }, 
        "brief_title": "A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Healthy"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy subjects\n\n          -  Body mass index (BMI) of 18.5-30 kg/m^2 (both incl.)\n\n        Exclusion Criteria:\n\n          -  History of or presence of cancer, diabetes, pancreatitis or any clinically relevant\n             cardiovascular diseases or other major disorders\n\n          -  Use of prescription or non-prescription medicinal products (except routine vitamins,\n             acetylsalicylic acid and paracetamol) within 3 weeks (or within 5 half-lives of the\n             medicinal product, whichever is longest) prior to the first dosing of semaglutide\n\n          -  Smoking, drug or alcohol abuse\n\n          -  Female of childbearing potential who is pregnant, breast-feeding or intend to become\n             pregnant or not using adequate contraceptive methods for the duration of the trial\n             and for 3 months following the last dose of semaglutide"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01766245", 
            "org_study_id": "NN9535-4010", 
            "secondary_id": [
                "2012-002212-20", 
                "U1111-1130-3931"
            ]
        }, 
        "intervention": {
            "arm_group_label": [
                "Formulation A followed by Formulation B", 
                "Formulation B followed by Formulation A"
            ], 
            "description": "For subcutaneous (s.c., under the skin), single dose administration at two separate dosing visits.", 
            "intervention_name": "semaglutide", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "mm", 
        "lastchanged_date": "May 27, 2013", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany", 
                    "zip": "10117"
                }
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Lene Jensen", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the plasma semaglutide concentration curve", 
                "safety_issue": "No", 
                "time_frame": "0-4 weeks after a single dose s.c. semaglutide administration"
            }, 
            {
                "measure": "Cmax, the maximum plasma semaglutide concentration", 
                "safety_issue": "No", 
                "time_frame": "20-40 hours after a single dose s.c. semaglutide administration"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01766245"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The area under the plasma semaglutide concentration curve", 
                "safety_issue": "No", 
                "time_frame": "From time 0 to infinity after a single dose s.c. semaglutide administration"
            }, 
            {
                "measure": "tmax, time to Cmax of semaglutide", 
                "safety_issue": "No", 
                "time_frame": "20-40 hours"
            }, 
            {
                "measure": "t\u00bd, terminal elimination half-life of semaglutide", 
                "safety_issue": "No", 
                "time_frame": "140-200 hours"
            }, 
            {
                "measure": "Incidence of adverse events (AEs)", 
                "safety_issue": "No", 
                "time_frame": "From first dosing to follow-up (5-7 weeks after the second dosing)"
            }, 
            {
                "measure": "Hypoglycaemic episodes", 
                "safety_issue": "No", 
                "time_frame": "From first dosing to follow-up (5-7 weeks after the second dosing)"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}